CONMED (CNMD) Q3 2026 Earnings Call Transcript

CONMED reported Q3 revenue of $335.6 million, down 70 basis points as reported after its gastroenterology product-line exit, while organic constant-currency sales grew 6.7%; adjusted EPS of $1.04 exceeded the high end of management’s expectations by $0.01. The company narrowed full-year organic sales growth guidance to 5%-5.5% from 5%-6%, citing a more measured Q4 outlook, but raised adjusted EPS guidance to $4.54-$4.61 from $4.48-$4.60. International growth and improving margins supported results, while domestic orthopedic sales declined 1.7% and Q3 free cash flow fell 3.6% year over year.

Analysis

The key read-through is execution quality, not the EPS beat: the higher EPS outlook does not erase a narrower organic-growth range, and the improved reported-revenue tailwind from FX can obscure underlying demand. International distributor order timing appears to have lifted Q3; because those channels carry lower gross margin, a normalization could pressure both growth and mix in Q4. Watch inventory and receivables for evidence that shipments pulled forward rather than merely shifted between periods.

AirSeal’s compatibility with da Vinci 5 is strategically useful to CONMED as it reduces adoption friction within Intuitive Surgical’s installed base; it is not yet proof of meaningful incremental utilization or revenue for either company. The nearer-term proof point is disposable pull-through, not capital placements alone. Likewise, smoke-evacuation mandates create a multi-quarter adoption runway, but facility implementation deadlines imply a lag between legislation and orders. OEM weakness remains a separate, less controllable demand channel. BioBrace’s Brazil clearance expands potential reach, but international indications and reimbursement may constrain near-term conversion.

Over 1–3 months, the risk is that Q4 growth tracks the lower end of the implied range as distributor timing unwinds and U.S. orthopedic commercial changes continue. Over 6–18 months, successful U.S. sales-force normalization and state compliance programs could broaden growth, while elevated interest expense and debt service compete with buybacks and M&A for cash. The constructive case is falsified by weaker organic growth, stalled U.S. ortho trends, or failure of direct smoke-evacuation growth to offset OEM softness; improved evidence would be repeatable disposable growth and stronger cash conversion.

Key Decisions for Investors

• No immediate earnings-chase trade in CNMD: the EPS guidance increase is partly a Q3 carry-through, while the lower organic-growth ceiling and distributor timing make the revenue trajectory less certain. Reassess after Q4 results and 2027 guidance.
• For a tactical CNMD long, wait for evidence that U.S. orthopedic growth is recovering and that AirSeal consumable demand sustains growth; size modestly until those indicators are reported. Cut the thesis if management reports continued domestic ortho deterioration or organic growth below the current 5%–5.5% outlook.
• Track state smoke-evacuation implementation deadlines against Buffalo Filter direct orders over coming quarters. Treat legislation as a catalyst watch, not a near-term revenue forecast; persistent OEM declines without direct-channel acceleration would weaken the growth thesis.
• Monitor free-cash-flow conversion, net leverage, and interest expense before assigning value to buybacks or prospective M&A. If cash conversion does not improve while repurchases continue, capital returns may slow deleveraging rather than create incremental equity value.